PhRMA supports the use of sound evidence to guide health care decisions, and we’re committed to developing tools to help patients, physicians and others make informed decisions.
Value assessments, or health technology assessments, are one tool that can support better value in health care. But current value assessments often fall short of the transparent, patient-centered approach we need. We’re providing support to develop value assessment tools that are open and transparent, rigorous and objective, support doctor-patient decision-making and look at value across the full spectrum of patient care. We’re also working to ensure that value assessments are not misused by government health agencies to impose patient access barriers and delays in care.
Concerns over rising health care costs have led some to call for government price setting for medicines. Some of these flawed ideas include government use of health technology assessments to make important decisions about the value of a treatment and whether patients should have access to an innovative medicine.
We only need to look abroad to see how the story ends when the government makes rigid judgements of clinical benefit to set prices for medicines. For instance, in Germany, just 68% of all new medicines are available. As we move toward a value-driven health care system, we should avoid one-size-fits-all policies that ignore patient differences and equity considerations and create significant access barriers.